TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Completed · Phase 3 · NCT04129502
Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
At a glance
- Research payments reported, 2025
- $345,862
- U.S. investigators named
- 4
- Sites paid
- 6
- Planned or actual enrollment
- 354
About the trial
- Sponsor
- Takeda
- Tested
- TAK-788 (drug), Pemetrexed (drug), Cisplatin (drug), Carboplatin (drug)
- Dates
- Started 2020-01-10; completion 2026-09-22
- Results posted
- Not yet
The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group. Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinua…
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $345,862 in research payments for this study in 2025 (26 payments).
Products named: Exkivity
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Joel W. Neal, M.D., PH.D. Medical Oncology · Stanford, CA
- Danny Nguyen, M.D. Hematology & Oncology · Huntington Beach, CA
- Pasi Antero Janne, MD PHD Medical Oncology · Boston, MA
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $164,158
- The Board of Trustees of the Leland Stanford Junior University $94,694
- Dana Farber PArtner Cancercare Inc $34,268
- Sarah Cannon Research Institute LLC $31,986
- Stanford Health Care, CA $20,248
- City of Hope National Medical Ctr $509
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.